New study using nuclear medicine and rare isotopes in the fight against cancer

London - In a national multicentre study, scientists at Lawson Health Research Institute and Western University are working to create rare isotopes that will be used as an important tool to help treat cancer.

Currently, radiation therapy is a staple in cancer treatment, with approximately 50 per cent of cancer patients receiving radiation at some point in their cancer journey. Although a very effective tool, traditional radiation therapies rely on intense beams of energy. These beams can kill cancer cells, but their use is limited to select locations, making them less suited for difficult-to-treat metastatic cancers that have spread to multiple sites.

“Cancer treatment has evolved over the years with targeted drugs that go straight to the cancer and advanced radiation therapy. However, radiation comes from an external source that can damage other areas in the body,” says Dr. Len Luyt, Lawson Scientist and Professor at Western. “We are now working to advance treatment further by combining radiation and targeted drug therapy.”

The therapies work like a homing device — using specially designed molecules to seek out and deliver radioactive isotopes directly to cancer cells, wherever they might be in the body.

The multidisciplinary research team involves researchers at Lawson, Western University, University of British Columbia, BC Cancer, TRIUMF, Simon Fraser University, Université Laval, Université de Sherbrooke, University of Toronto and University of Alberta.

“This is the holy grail of cancer treatment. These disease-targeting molecules circulate throughout the body, binding tightly to cancer cells in order to eliminate them with a highly localized blast of energy,” explains principal investigator Dr. François Bénard, Professor of Radiology and Associate Dean at UBC’s Faculty of Medicine, and Senior Executive Director of the BC Cancer Research Institute.

The London, Ontario team will focus on developing the radio pharmaceuticals at labs in the London Regional Cancer Program at LHSC, the Cyclotron located at St. Joseph’s Health Care London, and at Western. 

“The radio pharmaceuticals we are designing will be very specific to certain receptor proteins that are on cancer cells and not elsewhere on the body. This allows us to bring the isotopes to the cancer cells and clear it from the body so you have less side effects in other areas,” says Dr. Luyt. “This approach is showing promise in prostate cancer and now this team-based approach is looking at targeting any metastatic cancer.”

This collaborative research project has received $23.7 million in federal funding through the New Frontiers Research Fund (NFRF) over six years.

“We will establish Canada as a world leader in the field of nuclear medicine and ensure Canadian patients are the ones who benefit,” adds Dr. Bénard. “By developing these medicines in Canada and bringing them into local clinical trials, we will ensure Canadians have access to innovative cancer treatments sooner.”

The team hopes to bring multiple drug candidates into clinical trials in the coming years with the ultimate goal of developing an effective treatment for metastatic cancer patients. 

About Lawson Health Research Institute

Lawson Health Research Institute is one of Canada’s top hospital-based research institutes, tackling the most pressing challenges in health care. As the research institute of London Health Sciences Centre and St. Joseph’s Health Care London, our innovation happens where care is delivered. Lawson research teams are at the leading-edge of science with the goal of improving health and the delivery of care for patients. Working in partnership with Western University, our researchers are encouraged to pursue their curiosity, collaborate often and share their discoveries widely. Research conducted through Lawson makes a difference in the lives of patients, families and communities around the world. To learn more, visit www.lawsonresearch.ca.

About Western

Western delivers an academic experience second to none. Since 1878, The Western Experience has combined academic excellence with life-long opportunities for intellectual, social and cultural growth in order to better serve our communities. Our research excellence expands knowledge and drives discovery with real-world application. Western attracts individuals with a broad worldview, seeking to study, influence and lead in the international community.

Media Contacts
Celine Zadorsky

Senior Media Relations Consultant  
Communications & Public Engagement  
T: 519-685-8500 ext. 73502 
Celine.zadorsky@lhsc.on.ca